Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Chordoma × pembrolizumab × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 36 Melanoma 15 Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 9 Neoplasm Metastasis 8 Carcinoma, Non-Small-Cell Lung 8 Breast Neoplasms 8 Triple Negative Breast Neoplasms 7 Glioblastoma 7 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Lung Neoplasms 6 Histiocytoma, Malignant Fibrous 6 Gliosarcoma 6 Colorectal Neoplasms 6 Head and Neck Neoplasms 5 Carcinoma, Renal Cell 5 Carcinoma, Hepatocellular 5 Sarcoma, Synovial 4 Sarcoma, Kaposi 4 Osteosarcoma 4 Lymphoma 4 Liposarcoma 4 Hemangiosarcoma 4 Carcinoma, Merkel Cell 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Neurofibrosarcoma 3 Lymphoma, Non-Hodgkin 3 Kidney Neoplasms 3

Interventions

Nivolumab 6 Imatinib Mesylate 4 Ipilimumab 3 palbociclib 2 Specimen Handling 2 Radiosurgery 2 Protons 2 Proton Therapy 2 Pemetrexed 2 Magnetic Resonance Spectroscopy 2 Cyclophosphamide 2 Cetuximab 2 tazemetostat 1 spartalizumab 1 relatlimab 1 pembrolizumab 1 camrelizumab 1 avelumab 1 atezolizumab 1 apatinib 1 Zoledronic Acid 1 X-Rays 1 Tiragolumab 1 Thiotepa 1 Surveys and Questionnaires 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Radiation 1 Photochemotherapy 1 Phantoms, Imaging 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06794645 2025-01-27

Pembrolizumab and Pemetrexed for Progressive Chordoma

Saint John's Cancer Institute

Phase 2 Recruiting

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡